Table of Contents
ISRN Rheumatology
Volume 2011 (2011), Article ID 780356, 9 pages
http://dx.doi.org/10.5402/2011/780356
Research Article

The Contribution of Four Immunogenetic Markers for Predicting Persistent Activity in Patients with Recent-Onset Rheumatoid Arthritis or Undifferentiated Arthritis

1Department of Rheumatology, Virgen del Rocío University Hospital, 41013 Seville, Spain
2Biotechnology Area, Alto Guadalquivir Hospital, 23740 Andújar, Spain
3Department of Immunology, Virgen del Rocío University Hospital, 41013 Seville, Spain
4Private Practice, 1203 Geneva, Switzerland

Received 17 May 2011; Accepted 14 June 2011

Academic Editors: J. Bruges Armas and C. G. Mackworth-Young

Copyright © 2011 Sonsoles Reneses et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We assessed the contribution of four baseline markers—HLA-DRB1 shared epitope (SE), −308 tumor necrosis factor α gene promoter polymorphism, rheumatoid factor, and anticitrullinated peptide antibodies—for predicting persistent activity (DAS28 score ≥2.6) after one year of followup in a cohort of 201 patients with recent-onset rheumatoid arthritis (RA) or undifferentiated arthritis (UA) aged 16 years or older who had a 4-week to 12-month history of swelling of at least two joints. Patients had not been previously treated with corticosteroids or disease-modifying antirheumatic drugs (DMARD). In the best logistic regression model, only two variables were retained: SE positivity and number of DMARD administered (area under the curve = 76.4%; 95% CI: 69.2%, 84.4%; ๐‘ƒ < 0 . 0 0 1 ). The best linear regression model also included these two variables, explaining only 22.5% of the variability of DAS28 score. In this study, given an equal number of DMARD administered, the probability of persistent activity in patients with recent-onset RA or UA was significantly influenced by SE presence.